Effect of mutation order on myeloproliferative neoplasms.

BACKGROUND Cancers result from the accumulation of somatic mutations, and their properties are thought to reflect the sum of these mutations. However, little is known about the effect of the order in which mutations are acquired. METHODS We determined mutation order in patients with myeloproliferative neoplasms by genotyping hematopoietic colonies or by means of next-generation sequencing. Stem cells and progenitor cells were isolated to study the effect of mutation order on mature and immature hematopoietic cells. RESULTS The age at which a patient presented with a myeloproliferative neoplasm, acquisition of JAK2 V617F homozygosity, and the balance of immature progenitors were all influenced by mutation order. As compared with patients in whom the TET2 mutation was acquired first (hereafter referred to as "TET2-first patients"), patients in whom the Janus kinase 2 (JAK2) mutation was acquired first ("JAK2-first patients") had a greater likelihood of presenting with polycythemia vera than with essential thrombocythemia, an increased risk of thrombosis, and an increased sensitivity of JAK2-mutant progenitors to ruxolitinib in vitro. Mutation order influenced the proliferative response to JAK2 V617F and the capacity of double-mutant hematopoietic cells and progenitor cells to generate colony-forming cells. Moreover, the hematopoietic stem-and-progenitor-cell compartment was dominated by TET2 single-mutant cells in TET2-first patients but by JAK2-TET2 double-mutant cells in JAK2-first patients. Prior mutation of TET2 altered the transcriptional consequences of JAK2 V617F in a cell-intrinsic manner and prevented JAK2 V617F from up-regulating genes associated with proliferation. CONCLUSIONS The order in which JAK2 and TET2 mutations were acquired influenced clinical features, the response to targeted therapy, the biology of stem and progenitor cells, and clonal evolution in patients with myeloproliferative neoplasms. (Funded by Leukemia and Lymphoma Research and others.).

[1]  Christian Beisel,et al.  Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. , 2014, Blood.

[2]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[3]  W. Earnshaw,et al.  The chromosomal passenger complex (CPC): from easy rider to the godfather of mitosis , 2012, Nature Reviews Molecular Cell Biology.

[4]  G. Evan,et al.  p53 — a Jack of all trades but master of none , 2009, Nature Reviews Cancer.

[5]  L. Chin,et al.  Non-germline genetically engineered mouse models for translational cancer research , 2010, Nature Reviews Cancer.

[6]  E. Solary,et al.  JAK2V617F expression in mice amplifies early hematopoietic cells and gives them a competitive advantage that is hampered by IFNα. , 2013, Blood.

[7]  W. Hahn,et al.  Modelling the molecular circuitry of cancer , 2002, Nature Reviews Cancer.

[8]  W. Vainchenker,et al.  Analysis of the ten-eleven translocation 2 (TET2) gene in familial myeloproliferative neoplasms. , 2009, Blood.

[9]  Igor Jurisica,et al.  Isolation of Single Human Hematopoietic Stem Cells Capable of Long-Term Multilineage Engraftment , 2011, Science.

[10]  K. Rajewsky,et al.  Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice , 2011, Proceedings of the National Academy of Sciences.

[11]  R. Levine,et al.  Mutation in TET2 in myeloid cancers. , 2009, The New England journal of medicine.

[12]  Xiaochun Yu,et al.  TET2 promotes histone O-GlcNAcylation during gene transcription , 2012, Nature.

[13]  M. Stratton,et al.  Clinical and biological implications of driver mutations in myelodysplastic syndromes. , 2013, Blood.

[14]  Peter J. Campbell,et al.  Evolution of the cancer genome , 2012, Nature Reviews Genetics.

[15]  B. Garvik,et al.  Principles for the Buffering of Genetic Variation , 2001, Science.

[16]  E. Dermitzakis,et al.  Distinct clinical phenotypes associated with JAK2V617F reflect differential STAT1 signaling. , 2010, Cancer cell.

[17]  Carlo C. Maley,et al.  Clonal evolution in cancer , 2012, Nature.

[18]  K. Kinzler,et al.  Lessons from Hereditary Colorectal Cancer , 1996, Cell.

[19]  Peter W Zandstra,et al.  Rapid expansion of human hematopoietic stem cells by automated control of inhibitory feedback signaling. , 2012, Cell stem cell.

[20]  David A. Williams,et al.  Depletion of Jak2V617F myeloproliferative neoplasm-propagating stem cells by interferon-α in a murine model of polycythemia vera. , 2013, Blood.

[21]  J. D. Fitzpatrick,et al.  Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. , 2013, The New England journal of medicine.

[22]  Z. Chang,et al.  Mitotic control of dTTP pool: a necessity or coincidence? , 2007, Journal of biomedical science.

[23]  Yi Zhang,et al.  Role of Tet proteins in 5mC to 5hmC conversion, ES-cell self-renewal and inner cell mass specification , 2010, Nature.

[24]  Peter A. Jones,et al.  A decade of exploring the cancer epigenome — biological and translational implications , 2011, Nature Reviews Cancer.

[25]  K. Anderson,et al.  Genetic variegation of clonal architecture and propagating cells in leukaemia , 2011, Nature.

[26]  M. Murakami,et al.  Differential effects of hydroxyurea and INC424 on mutant allele burden and myeloproliferative phenotype in a JAK2-V617F polycythemia vera mouse model. , 2013, Blood.

[27]  K. Döhner,et al.  TET genes: new players in DNA demethylation and important determinants for stemness. , 2011, Experimental hematology.

[28]  Mingming Jia,et al.  COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer , 2010, Nucleic Acids Res..

[29]  J. Dick,et al.  Revised map of the human progenitor hierarchy shows the origin of macrophages and dendritic cells in early lymphoid development , 2010, Nature Immunology.

[30]  D. Kent,et al.  Self-Renewal of Single Mouse Hematopoietic Stem Cells Is Reduced by JAK2V617F Without Compromising Progenitor Cell Expansion , 2013, PLoS biology.

[31]  Anindya Dutta,et al.  Genomic instability in cancer. , 2013, Cold Spring Harbor perspectives in biology.

[32]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[33]  J. Pines,et al.  APC/CCdh1 Targets Aurora Kinase to Control Reorganization of the Mitotic Spindle at Anaphase , 2008, Current Biology.

[34]  B. Garvik,et al.  Principles for the buffering of genetic variation. , 2001 .

[35]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[36]  A. Ashworth,et al.  Genetic Interactions in Cancer Progression and Treatment , 2011, Cell.

[37]  Jason Gotlib,et al.  A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. , 2012, The New England journal of medicine.

[38]  P. Campbell,et al.  JAK2 V617F impairs hematopoietic stem cell function in a conditional knock-in mouse model of JAK2 V617F-positive essential thrombocythemia. , 2010, Blood.

[39]  J M Piret,et al.  Differential cytokine effects on primitive (CD34+CD38-) human hematopoietic cells: novel responses to Flt3-ligand and thrombopoietin , 1996, The Journal of experimental medicine.